Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer

Bcl-2 is overexpressed in about a half of human cancers and 50–70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powerful tools for specific gene silencing and molecular...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Ibrahim Tekedereli, S Neslihan Alpay, Ugur Akar, Erkan Yuca, Cristian Ayugo-Rodriguez, He-Dong Han, Anil K Sood, Gabriel Lopez-Berestein, Bulent Ozpolat
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2013-01-01
Reeks:Molecular Therapy: Nucleic Acids
Onderwerpen:
apoptosis
autophagy
Bcl-2
breast cancer
chemotherapy
estrogen receptor
gene silencing
liposome
nanoparticles
nanotherapeutics
programmed cell deathsiRNA
Online toegang:http://www.sciencedirect.com/science/article/pii/S2162253116301780
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items